Synerase®

Synerase®

Systemic Enzyme Formula

90 Enteric Coated Tablets ( SKU: 9247, NPN: 80042607 )

Benefits

  • Formulated for both anti-inflammatory, antifibrinolytic and immune-modulating activity as well as digestive benefit
  • Diverse proteolytic activity with a broad range physiological functions and clinical uses extending well beyond protein digestion
  • Unique, clinically effective, concentrated enzyme formulation containing pancreatic enzymes, papain, Peptizyme SP and bromelain
  • Enteric coated tablets help protect the enzyme from the acidic environment of the stomach, allowing the high enzyme activity level to reach the small intestine

Feature Summary

Synerase is a unique proteolytic enzyme combination with diverse clinical benefits, showing efficacy both for systemic inflammation as well as digestive function. This multienzyme formulation contains digestive enzymes with physiological influences extending well beyond protein digestion. This is in part due to the increase in food allergies as a result of incomplete protein digestion, which may be responsible for more systemic effects.1 Beyond protein digestion, bromelain has been shown to reduce blood viscosity, prevent aggregation of blood platelets, reduce levels of prostaglandin E2 and thromboxane A2, and in an open study it improved symptoms of mild, acute knee pain.2,3,4 Bromelain also has demonstrated immunomodulatory effects in a variety of models, preventing neutrophil migration in response to IL-8 during inflammation, and inhibiting pro-inflammatory chemokine and cytokine secretion.5,6,7

Another component of Synerase, Peptizyme SP, has been evaluated in a number of clinical trials, demonstrating anti-inflammatory, anti-edemic and fibrinolytic properties, resulting in a significant reduction in symptoms for both acute and chronic ear, nose or throat disorders.8 It has also shown antimicrobial properties, modulating proteins involved in bacterial colonization, persistence and invasion.9

Medicinal Ingredients

Serving Size: 2 Enteric Coated Tablets
Servings Per Container: 45

Each Tablet Contains:
Pancreatic Enzymes 8x (Sus scrofa) (pancreas)..................................200 mg (83,200 USP units)
Alpha-Amylase Activity.................................................................... 40,000 USP units
Protease Activity.............................................................................. 40,000 USP units
Lipase Activity.................................................................................... 3,200 USP units
Papain (Carica papaya) (fruit).............................................................. 120 mg (3,600,000 USP PU)
Peptizyme SPTM Serratiopeptidase (Serratia spp.) (whole cell).............52 mg (10,400 SU)
Bromelain (Ananas comosus var. comosus) (stem)............................... 50 mg (640,000 FCC PU)
USP (United States Pharmacopoeia), FCC (Food Chemical Codex), PU (Papain Unit), SU (Serratiopeptidase Unit)

Non-Medicinal Ingredients

Microcrystalline cellulose, purified water, enteric coating (purified water, ethylcellulose, medium chain triglycerides, oleic acid, carbohydrate gum [cellulose], glycerin, sodium alginate, stearic acid), croscarmellose sodium, vegetable grade magnesium stearate (lubricant).

Allergens:

Contains no artificial colours, preservatives, or sweeteners; no dairy, sugar, wheat, gluten, yeast, soy, egg, fish, shellfish, salt, tree nuts, or GMOs. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.

Contraindications

Do not use if you are pregnant or breastfeeding, have gastrointestinal lesions/ulcers, heart or blood vessel problems, high blood pressure, kidney or liver disorder, bleeding disorder, hemorrhoids, are taking anticoagulants/blood thinners, anti-inflammatory agents, or are sensitive to pancreatic enzymes or pork proteins. Consult a health care practitioner if symptoms persist or worsen, if you have persistent swelling, diabetes, pancreatitis, pancreatic exocrine insufficiency or cystic fibrosis, if you are taking other enzyme products or antibiotics, are having surgery, had major trauma, or if you have an allergy to latex or fruits such as avocado, banana, chestnut, passion fruit, fig, melon, mango, kiwi, pineapple, peach and tomato. Hypersensitivity/allergy, dizziness, headaches, difficulty breathing, rash, nausea, vomiting, abdominal pain/epigastric pain and/or heartburn and diarrhea have been known to occur, in which case discontinue use and consult a health care practitioner. Keep out of reach of children.

Drug Interactions

Synerase has fibrinolytic activity, and when taken with antiplatelet or anticoagulant drugs, may increase the risk of bruising and/or bleeding. Bromelain may decrease amoxicillin metabolism.

  1. Untersmayr E, et al. The effect of gastric digestion on food allergy. Curr Opin Allergy Clin Immunol. 2006 Jun;6(3):214-9.
  2. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 2001;58:1234-45.
  3. Juhasz B, et al. Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardium. Am J Physiol Heart Circ Physiol. Mar 2008;294(3):H1365-1370.
  4. Walker AF, et al. Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. Phytomedicine 2002 Dec;9(8):681-6.
  5. Fitzhugh, et al. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol. Jul 2008;128(1):66-74.
  6. Onken JE, et al. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol. Mar 2008;126(3):345-352.
  7. Secor ER, et al. Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma. Evid Based Complement Alternat Med. Mar 2008;5(1):61-69.
  8. Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.
  9. Artini M, et al. A new anti-infective strategy to reduce adhesion-mediated virulence in Staphylococcus aureus affecting surface proteins. Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):661-72.